![]() |
|
|
Vol. 298, Issue 3, 894-899, September 2001
Department of Drug Delivery Research, Graduate School of Pharmaceutical Sciences (Y.Y., N.K., T.N., M.N., Y.T., M.H.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (R.T.), Kyoto University, Sakyo-ku, Kyoto, Japan.
| |
Abstract |
|---|
|
|
|---|
Our previous study demonstrated that the combination of mannosylated superoxide dismutase (Man-SOD) and succinylated catalase (Suc-CAT), both of which are designed to be targeted to liver nonparenchymal cells, is a promising approach to prevent the initial phase of hepatic ischemia/reperfusion injury induced by occlusion of the portal vein for 30 min followed by a 1-h reperfusion in mice. In this study, the preventive effects of these agents were examined on late-phase injury mediated by infiltrating neutrophils, a more severe condition than the initial one. Administration of Suc-CAT alone or with Man-SOD to mice undergoing hepatic ischemia/reperfusion significantly suppressed the expression of intercellular adhesion molecule-1 along the hepatic sinusoid and prevented neutrophil infiltration in the liver. Man-SOD and Suc-CAT also prevented the increase in plasma glutamic pyruvic transaminase and glutamic oxaloacetic transaminase activities after reperfusion lasting 3 and 6 h. Histological evaluation of liver tissues confirmed the efficacy of this treatment, suggesting that these SOD and catalase derivatives have the ability to suppress neutrophil-induced hepatic injury. These results demonstrate that targeted delivery of antioxidant enzymes to liver nonparenchymal cells is a promising approach to reducing the reactive oxygen species produced by Kupffer cells and neutrophils infiltrating into the tissue. Since Suc-CAT is partially taken up by hepatocytes via a catalase-specific uptake mechanism, such a fraction could also be involved in its preventive effect against the injury.
| |
Introduction |
|---|
|
|
|---|
Hepatic
ischemia followed by reperfusion results in severe injuries that
contribute to the morbidity and mortality associated with shock,
transplantation, and liver surgery. It has been generally accepted that
reactive oxygen species (ROS) contribute to hepatic ischemia/reperfusion injury (McCord, 1985
), and such injury has been
demonstrated to occur in a biphasic pattern involving initial- and
subsequent-phase responses (Jaeschke et al., 1991
). Activated Kupffer
cells generating an increasing amount of ROS mainly mediate the initial
phase of injury. These cells are activated during ischemia (Rymsa et
al., 1991
) and are further stimulated by complement activation during
reperfusion (Jaeschke et al., 1993
).
The initial responses of the ischemia/reperfusion injury trigger the
infiltration of neutrophils into postischemic liver (Jaeschke et al.,
1991
). The recruitment of neutrophils results from a complex series of
ischemia-induced cellular responses in the liver and changes in the
vasculature that serve to alter the adherent characteristics of the
neutrophils (Jaeschke et al., 1996
). These include the increased
expression of adhesion molecules, such as intercellular adhesion
molecule-1 (ICAM-1) (Farhood et al., 1995
). ICAM-1 is expressed on
endothelial cells and plays a key role in the potent adhesion of
neutrophils and their transendothelial migration (Luscinskas et al.,
1991
). The accumulation of neutrophils in the liver is reported to take
place mainly between 30- and 60-min postreperfusion, but they do not
spontaneously release ROS in the vasculature (Jaeschke et al., 1991
).
The respiratory burst of neutrophils adhering to a biological surface,
such as endothelial cells or extracellular matrix proteins, is
characterized by a lag-phase of 30 to 90 min between the adherence of
activated neutrophils and the subsequent long-lasting ROS formation
(Jaeschke, 1991
). Thus, activated neutrophils play a central role in
the later phase of hepatic injury by releasing ROS (Jaeschke, 1991
).
In previous studies, we developed various derivatives of superoxide
dismutase (SOD) and catalase by carrying out chemical modifications and
demonstrated that targeted delivery of SOD and catalase to liver
nonparenchymal cells is a promising approach to prevent hepatic
ischemia/reperfusion injury (Fujita et al., 1992a
,b
; Yabe et al.,
1999b
). Among the various combinations, it was that the administration
of succinylated catalase (Suc-CAT) and mannosylated SOD (Man-SOD) was
very effective in preventing initial hepatic injury at 1 h after
reperfusion (Yabe et al., 1999b
). However, the preventive effects of
such treatments on the later phase of the injury have not been
investigated. The subsequent phase of the injury, which is mainly
caused by infiltrating neutrophils, is more severe than the initial one
and leads to irreversible tissue damage (Jaeschke et al., 1991
).
Therefore, in the present study, we examined the effect of catalase and
SOD derivatives on the late phase of ischemia/reperfusion injury by examining the plasma glutamic oxaloacetic transaminase (GOT) and glutamic pyruvic transaminase (GPT) levels at 3 and 6 h after reperfusion and ICAM-1 expression and neutrophil accumulation in the liver.
| |
Materials and Methods |
|---|
|
|
|---|
Animals. Male ddY mice (10-weeks old, 40-50 g) were purchased from the Shizuoka Agricultural Cooperative Association for Laboratory Animals (Shizuoka, Japan). Animals were maintained under conventional housing conditions. This study was carried out in accordance with the Principles of Laboratory Animal Care as adopted and promulgated by the U.S. National Institutes of Health.
Chemicals. Bovine liver catalase (40,000 U/mg) was purchased from Sigma (St. Louis, MO). Recombinant human SOD (111-Ser) was supplied by Asahi Kasei (Tokyo, Japan). Rat anti-mouse ICAM-1 antibody (KAT-1) was purchased from Dainippon Pharmaceutical Co., Ltd. (Osaka, Japan). All other chemicals were of the highest grade available.
Synthesis and Characterization of Catalase and SOD
Derivatives.
The synthesis of Suc-CAT and Man-SOD was performed as
reported previously (Fujita et al., 1992b
; Yabe et al., 1999b
).
In brief, 100 mg of catalase was dissolved in 10 ml of 0.2 M Tris
buffer (pH 8.65), and 46 mg of succinic anhydride was added. The
mixture was then stirred for 18 h at room temperature. The
reaction mixture was subjected to column chromatography (Toyopearl
HW-55S, Tosoh Co., Tokyo, Japan), and fractions with larger molecular
weights were collected. Man-SOD was synthesized by reacting SOD with
2-imino-2-methoxyethyl 1-thiomannoside. Each derivative was washed,
concentrated by ultrafiltration (molecular weight cut-off, 200,000 for
Suc-CAT and 20,000 for Man-SOD, respectively) against distilled water,
and lyophilized.
Hepatic Ischemia/Reperfusion Experiment. Male ddY mice were anesthetized with a peritoneal injection of pentobarbital sodium (50 mg/kg). An incision was made in the abdomen, and the portal vein and hepatic artery were occluded with a vascular clamp for 30 min to induce hepatic ischemia. Then, blood was allowed to flow through the liver again (reperfusion). Saline (control), catalase derivatives (10,000 U/kg), Man-SOD (10,000 U/kg), or a combination of Suc-CAT and Man-SOD (10,000 U/kg for each) was administered twice through the tail vein 5 min before and 60 min after re-establishing blood flow. After an appropriate period of reperfusion (30, 45, 60, 120, 180, 360, 720 min), blood was collected from the vena cava, and plasma was obtained by centrifugation. GPT and GOT activities, as indicators of hepatocyte injury during reperfusion, were assayed using commercial test reagents.
Histological Examination.
Liver tissues after 30 or 180 min
of reperfusion were excised and subjected to histological examination.
Tissue samples were fixed with 10% neutral buffered formalin, embedded
in paraffin blocks, and 5-µm-thick sections were cut. For
immunohistochemical staining of ICAM-1, the sections from the liver
were stained after 30 min of reperfusion with a rat anti-mouse ICAM-1
antibody, according to the method reported previously (Hsu et al.,
1981
). Furthermore, the sections from the liver were stained after 180 min of reperfusion with hematoxylin and eosin to observe hepatic injury.
Evaluation of Neutrophil Infiltration.
Neutrophil
infiltration into liver tissue was evaluated by a method reported
previously (Farhood et al., 1995
). Briefly, liver tissues were excised
after 30 or 45 min of reperfusion to make the sections, and neutrophils
in the liver section were stained using the AS-D chloroacetate
esterase technique (Moloney, 1960
). Neutrophils were identified by
positive staining and morphology and were counted in 25 high-power
fields (HPF) (400×) using a Nikon Labophot microscope (Tokyo,
Japan). Only those neutrophils were counted that were present within
sinusoids or extravasated into the tissue, those in large hepatic
vessels such as venules were not.
Statistical Analysis. Differences were statistically evaluated by one-way analysis of variance followed by the Student-Newman-Keuls multiple comparison test at a significance level of p < 0.05.
| |
Results |
|---|
|
|
|---|
ICAM-1 Expression in the Liver Detected by Immunohistochemical
Staining.
In a previous study, pretreatment with catalase was
effective in maintaining low GPT and GOT levels only at high doses
after 60 min of reperfusion (Yabe et al., 1999a
). Suc-CAT, which is taken up by liver nonparenchymal cells, was very effective in inhibiting the production of hepatic injury at lower doses, and its
effect was increased by coadministering Man-SOD (Yabe et al., 1999b
).
First we evaluated the effects of Suc-CAT and/or Man-SOD on ICAM-1
expression in the liver section from the mice subjected to 30 min of
ischemia followed by 30 min of reperfusion. Staining of control liver
sections with a monoclonal anti-ICAM-1 antibody showed weak expression
of ICAM-1 on sinusoidal endothelial cells and no expression on
hepatocytes (Fig. 1A).
Ischemia/reperfusion followed by saline injection resulted in an
increased expression of ICAM-1 on both endothelial cells and
hepatocytes (Fig. 1B). The increase in ICAM-1 expression was prevented
to some extent by catalase administration (Fig. 1C). The pattern of
ICAM-1 expression in the specimens of mouse liver receiving Suc-CAT and
Man-SOD was indistinguishable from that of the control group (Fig. 1D).
|
Neutrophil Accumulation in the Liver.
The number of
neutrophils accumulating in the liver after reperfusion was counted
under a microscope. After 30 or 45 min of reperfusion, 2.3 or 3.5 times
as many neutrophils, respectively, accumulated in the liver compared
with control mice (p < 0.05, p < 0.001) (Fig. 2). After 180 min of
reperfusion, the number of neutrophils increased to 373 ± 68 (per
25 HPF), which was 7.1 times as many as that of control mice. At 45 min
of reperfusion (Fig. 2), treatment with Man-SOD, catalase, and Suc-CAT
reduced the number of neutrophils in the liver by 44, 57, and 62%,
respectively. Significant differences were observed between each
treated group and saline-treated group (p < 0.001). In
the Man-SOD and Suc-CAT treatment group, the level was almost the same
as in the control group.
|
Time Course of Plasma GOT and GPT Levels after Reperfusion
following a 30-Min Period of Ischemia.
During the 30-min period of
ischemia, plasma GOT and GPT levels did not significantly increase.
After re-establishing hepatic blood flow, however, both activities were
continuously elevated. Their activities became significantly higher
after 30 min of reperfusion (p < 0.01) and reached a
maximum after 6 h of reperfusion (Fig. 3). After 6 h of reperfusion, the
values of GOT and GPT were 9 and 35 times greater, respectively, than
those before ischemia and were significantly higher than those after 60 min of reperfusion (GOT, p < 0.05; GPT,
p < 0.01), indicating more severe injury occurring at
the later phase of the reperfusion.
|
Prevention of Later Phase Hepatic Ischemia/Reperfusion Injury by
Catalase and SOD Derivatives.
The effect of catalase and SOD
derivatives on plasma GOT and GPT activities after a longer reperfusion
of 180 or 360 min was examined. Measured at 180 min after reperfusion,
the plasma GOT and GPT levels remained significantly lower than those
in saline-treated mice following injection of Suc-CAT or coinjection of
Suc-CAT and Man-SOD (p < 0.01) (Fig.
4, A and B, panel a). These preventive effects were maintained until 360 min after reperfusion (Fig. 4, A and
B, panel b).
|
Liver Tissue Damage.
Figure 5
shows the liver specimens from mice suffering from ischemia (30 min)/reperfusion (180 min) followed by treatment with saline (A),
catalase (B), Suc-CAT (C), or Man-SOD and Suc-CAT (D). The sections
from the saline- and CAT-treated mice had lots of necrotic and/or
damaged cells. In contrast, hepatocellular damage was prevented, and
the integrity of sinusoids was almost completely maintained in the
livers of mice treated with Suc-CAT alone or Suc-CAT and Man-SOD.
|
| |
Discussion |
|---|
|
|
|---|
SOD is an enzyme that converts superoxide anion to hydrogen
peroxide, and catalase is an enzyme that can detoxify hydrogen peroxide. Although these enzymes have been used to prevent various ROS-mediated injuries, inadequate delivery to target sites may be the
cause of the controversial results obtained so far (Atalla et al.,
1985
; Chiu and Toledo-Pereyra, 1987
; Flye and Yu, 1987
) because these
enzymes can detoxify ROS only at the sites to which they are delivered.
Cell-specific targeting is a promising approach to improve the
pharmacological activity of these biologically active agents.
In previous studies, the targeted delivery of SOD and catalase to liver
nonparenchymal cells by mannosylation or succinylation has been
demonstrated (Fujita et al., 1992b
; Yabe et al., 1999b
). Kupffer and
sinusoidal endothelial cells, which account for the majority of liver
nonparenchymal cells, possess mannose receptors that recognize and
internalize ligands containing mannose, such as Man-SOD and Man-CAT,
and scavenger receptors that recognize polyanions, such as succinylated
proteins (e.g., Suc-CAT). Therefore, mannosylation or succinylation
greatly increases the amount of these enzymes targeted to the liver
nonparenchymal cells where ROS are generated in large quantities during
the initial phase of the ischemia/reperfusion injury. Compared with
other types of enzyme derivatives, these liver nonparenchymal cells
targeted SOD, and catalase derivatives exhibited more promising effects in preventing the initial phase of hepatic ischemia/reperfusion injuries (Fujita et al., 1992a
; Yabe et al., 1999b
). Among the various combinations, Man-SOD and Suc-CAT have shown the greatest efficacy in preventing hepatic injury (Yabe et al., 1999b
).
Previous results reported from our laboratory demonstrated that
the amount (on a cell-number basis) of succinylated proteins taken up
by liver endothelial cells was 3.3 times as large as Kupffer cells in
rats (Furitsu et al., 1997
). On the other hand, the uptake of
mannosylated proteins took place on both the endothelial cells and
Kupffer cells at a similar level (Ogawara et al., 1999
). Therefore, after the administration of Suc-CAT and Man-SOD, liver endothelial cells could possess a higher level of catalase activity than that of
SOD activity, whereas Kupffer cells could mainly have SOD activity. Therefore, a plausible mechanism of the protection by Suc-CAT and
Man-SOD is the dismutation of superoxide anion that Kupffer cells
generate by Man-SOD followed by Suc-CAT-mediated elimination of
hydrogen peroxide, which is a stable amphiphilic molecule that can
diffuse cellular membrane.
Ischemia/reperfusion injury is supposed to consist of an initial and a
subsequent phase. In the initial phase of the injury, ROS are mainly
released from Kupffer cells (Jaeschke, 1991
). Then, these ROS recruit
and activate neutrophils (Jaeschke et al., 1991
). Once activated and
attached to endothelial cells, the neutrophils may exacerbate tissue
injury by generating ROS and secreting several proteases, such as
myeloperoxidase, elastase, and collagenase (Jaeschke, 1991
). Neutrophil
sequestration may be explained by two mechanisms: 1) exposure of serum
to oxidants results in generation of chemotaxin(s) that contribute to
directed migration of neutrophils into inflamed tissue (McCord, 1985
),
and 2) activation of cell-surface adhesion molecules by oxidants
mediates adhesive interactions between neutrophils and endothelial
cells (Lewis et al., 1988
; Lo et al., 1993
). It has been reported that
cell adhesion molecules play a central role in leukocyte-endothelial
interactions (Farhood et al., 1995
). ICAM-1 is constitutively present
on endothelial cells and on some other cell types, including
lymphocytes, fibroblasts, hepatocytes, and epithelial cells (Jaeschke
et al., 1996
). ICAM-1 is known to be involved as a counter receptor to
CD11/CD18 integrin in the strong adhesion of neutrophils to endothelial
cells and transendothelial migration (Jaeschke et al., 1996
).
Endothelial ICAM-1 can be induced within 1 h of stimulation of
endothelial cells by means of cytokines, including tumor necrosis
factor-
, interleukin-1, and interferon-
(Jaeschke et al., 1996
).
Hydrogen peroxide can also induce endothelial ICAM-1 through activation of transcriptional factors, such as nuclear factor kappa B (Lewis et
al., 1988
; Schreck et al., 1991
; Lo et al., 1993
). It has been reported
that the expression of ICAM-1 is increased on the sinusoidal endothelial cells of ischemic lesions (Farhood et al., 1995
), and
hydrogen peroxide increases ICAM-1 mRNA and protein expression (Lo et
al., 1993
; Farhood et al., 1995
).
Based on of such evidence, we examined ICAM-1 expression (Fig. 1) and
neutrophil accumulation (Fig. 2) in the mice liver after hepatic
ischemia/reperfusion. Hepatic ischemia/reperfusion resulted in a marked
increase in ICAM-1 expression on the endothelial cells and hepatocytes.
Furthermore, many neutrophils were found infiltrating in liver tissues.
Neutrophil accumulation began at 30 to 45 min of reperfusion and
continued to 3 h of reperfusion. These results were not consistent
with a previous study (Jaeschke, 1991
), but experimental procedures
could account for such differences. Administration of catalase,
Suc-CAT, and Man-SOD reduced both the ICAM-1 expression and neutrophil
infiltration into the liver. Among them, administration of Suc-CAT
alone or with Man-SOD markedly reduced both. Since up-regulation of
ICAM-1 is brought by intracellular transcription, these results suggest
that these catalase and SOD derivatives could eliminate intracellular
ROS in the sinusoidal endothelial cells.
After transendothelial migration, neutrophils attached to the
hepatocyte aggravate the later phase of reperfusion injury by generating cytotoxic mediators, such as ROS (Komatsu et al., 1992
; Jaeschke et al., 1996
). Therefore, as the next step, we examined the
protective effect of SOD and catalase derivatives targeted to the liver
nonparenchymal cells in long-term reperfusion injury. The plasma GOT
and GPT activities gradually increased with time after reperfusion and
reached a maximum at 6 h of reperfusion, indicating that more
severe injury occurs at the late phase of reperfusion (Fig. 3).
Although the catalase and SOD derivatives, Suc-CAT and Man-SOD, used in
the present study were effective in preventing the leakage of GOT and
GPT up to 1 h of reperfusion when given as a single administration
of 10,000 U/kg (Yabe et al., 1999b
), the same dose of these derivatives
administered once at 5 min before reperfusion had no significant
preventive effect on the long-term injury, determined at 3 or 6 h
(data not shown). These results suggest that the reduction in ROS
generation by a single administration of these enzymes or their
combination is not sufficient to prevent the subsequent phase of the
injury. Ligands internalized by receptor-mediated endocytosis are known to be sorted to endosomes, then to lysosomes where they are degraded by
proteolysis (Pontow et al., 1992
). This degradation might limit the
duration of the efficacy of the enzyme derivatives if ROS are
continuously released. We then tried to administer these derivatives on
two occasions, at 5 min before and 60 min after reperfusion. This
protocol made it possible to maintain the plasma GOT and GPT levels of
mice treated with Suc-CAT alone or with Man-SOD at significantly lower
levels than those of saline- or CAT-treated mice, following injection
at least 6 h after reperfusion (Fig. 4). Histological evaluation
of liver tissues also confirmed the efficacy of Man-SOD and Suc-CAT
(Fig. 5D). In the Man-SOD and Suc-CAT group, the integrity of sinusoid
was almost completely maintained, suggesting that protection of
sinusoidal endothelial cells is important in preventing hepatic injury.
Prevention of ICAM-1 expression and subsequent neutrophil accumulation
in the liver could be one reason why the combined use of Man-SOD and Suc-CAT is effective on both the initial and subsequent phases of
ischemia/reperfusion injury in the liver. These findings indicate that
the simultaneous cell-specific targeting of catalase and SOD to liver
nonparenchymal cells is an effective approach for preventing not only
the initial hepatic ischemia/reperfusion injury but also that occurring
later by eliminating both extracellular ROS generated by Kupffer cells
and intracellular ROS in sinusoidal endothelial cells.
Recent studies have demonstrated that intracellular oxidative stress in
hepatocytes is also important in hepatocyte cell death (Jaeschke et
al., 1999
; Kumamoto et al., 1999
). Mitochondria seem to be the major
source that produces ROS intracellularly (Dawson et al., 1993
).
Superoxide induces hepatocyte apoptosis during the early phase of
reperfusion after hepatic ischemia (Sasaki et al., 1998
), and apoptosis
of hepatocytes acts as a signal for sinusoidal sequestration and
transendothelial migration of neutrophils (Lawson et al., 1998
).
Although the contribution and importance of apoptosis in the hepatic
injury are still controversial (Cursio et al., 1999
; Gujral et al.,
2001
), there is no doubt that intracellular ROS contribute to the
reperfusion injury after hepatic ischemia. Our previous study suggests
that 111In-Man-CAT and
111In-Suc-CAT are recognized by not only the
mannose and scavenger receptors on liver nonparenchymal cells but also
by the mechanism specific for catalase on hepatocytes (Yabe et al.,
1999b
). Therefore, a part of Suc-CAT is taken up by hepatocytes after
systemic administration, and it may show the enzymatic activity against
intracellular ROS following hepatic ischemia/reperfusion. Further
studies are needed to evaluate how much these catalase derivatives,
which are delivered to hepatocytes, can eliminate intracellular ROS.
In conclusion, we have demonstrated that cell-specific targeted delivery of catalase and SOD to liver nonparenchymal cells is a promising strategy for inhibiting hepatic ischemia/reperfusion injuries. This approach is effective not only in eliminating ROS produced by Kupffer cell but also in decreasing neutrophil accumulation in the liver by inhibiting expression of ICAM-1 along sinusoidal endothelial cells.
| |
Acknowledgments |
|---|
We thank Dr. Mari Kojima for technical assistance with immunohistochemical staining.
| |
Footnotes |
|---|
Accepted for publication May 25, 2001.
Received for publication March 2, 2001.
This work was supported in part by a grant-in-aid for Scientific Research from the Ministry of Education, Science, Sports, and Culture of Japan.
Address correspondence to: Dr. Mitsuru Hashida, Department of Drug Delivery Research, Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshidashimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan. E-mail: hashidam{at}pharm.kyoto-u.ac.jp
| |
Abbreviations |
|---|
ROS, reactive oxygen species; SOD, superoxide dismutase; ICAM-1, intercellular adhesion molecule-1; CAT, catalase; Suc-CAT, succinylated CAT; Man-CAT, mannosylated CAT; Man-SOD, mannosylated SOD; HPF, high-power fields; GPT, glutamic pyruvic transaminase; GOT, glutamic oxaloacetic transaminase.
| |
References |
|---|
|
|
|---|
release by activated Kupffer cells upon hypoxia-reoxygenation.
Am J Physiol
261:
G602-G607
B transcription factor and HIV-1.
EMBO (Eur Mol Biol Organ) J
10:
2247-2258[Medline].This article has been cited by other articles:
![]() |
K. Hyoudou, M. Nishikawa, Y. Kobayashi, Y. Kuramoto, F. Yamashita, and M. Hashida Analysis of In Vivo Nuclear Factor-{kappa}B Activation during Liver Inflammation in Mice: Prevention by Catalase Delivery Mol. Pharmacol., February 1, 2007; 71(2): 446 - 453. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Pacher, J. S. Beckman, and L. Liaudet Nitric Oxide and Peroxynitrite in Health and Disease Physiol Rev, January 1, 2007; 87(1): 315 - 424. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Gordon, F. Li, X. Zhang, W. Wang, X. Zhao, and A. Nayyar The combined CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks neutrophil infiltration, pyrexia, and pulmonary vascular pathology in endotoxemic animals J. Leukoc. Biol., December 1, 2005; 78(6): 1265 - 1272. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. N. Hines, J. M. Hoffman, H. Scheerens, B. J. Day, H. Harada, K. P. Pavlick, S. Bharwani, R. Wolf, B. Gao, S. Flores, et al. Regulation of postischemic liver injury following different durations of ischemia Am J Physiol Gastrointest Liver Physiol, March 1, 2003; 284(3): G536 - G545. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Jaeschke Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning Am J Physiol Gastrointest Liver Physiol, January 1, 2003; 284(1): G15 - G26. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||